NICE has introduced important appraisal reforms for 2025 that will directly impact manufacturers preparing STA and HST submissions. From the severity modifier to refined HST criteria and the ILAP relaunch, these updates reshape the UK market access environment.
To help you stay ahead, we’ve created a NICE Summary Guide that explains the reforms and highlights what they mean for your submission strategy.
Why Download the NICE Summary Guide?
- Understand the 2025 reforms in plain language – no need to navigate multiple NICE publications.
- Learn what changes mean for STA & HST submissions – adapt your evidence strategy with confidence.
- See how ILAP fits in – discover opportunities for faster access.
- Stay compliant and competitive – ensure your submissions meet NICE’s updated requirements.
Who Should Read This Guide?
- Pharma & biotech manufacturers preparing for UK market access
- Market access and HEOR teams needing clarity on the 2025 NICE reforms
- Regulatory and clinical development leads aligning evidence strategies
- Anyone navigating the NICE submission process in 2025 and beyond